Alnylam and Benitec Form Alliance on Fundamental Intellectual Property for RNAi Therapeutics
In addition, Alnylam will provide Benitec with options to take up to five InterfeRx(TM) exclusive licenses to pursue synthetic RNAi therapeutics against mutually agreed, specific targets. The InterfeRx program was instituted by Alnylam to grant licenses for RNAi therapeutics against targets that fall outside Alnylam's core strategic interests. Upon the exercise of each granted InterfeRx option, Alnylam will receive license fees and be entitled to receive milestone payments and royalties on synthetic RNAi therapeutics developed by Benitec.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.